Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor (PAMSARC)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511935-86-00

Acronym

HEROES-AYA I

Enrollment

Registered

2024-11-12

Start date

2024-12-18

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

8806/3, 9040/3, 9041/3, 9042/3, 9043/3 Locally advanced or metastatic desmoplastic small round cell tumor ICD-O3, Locally advanced or metastatic synovial sarcoma ICD-O3

Brief summary

Progression free survival (PFS), measured from study registration to radiologically confirmed disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first (censoring of patients without an event at date of last follow-up)

Detailed description

Overall survival (OS), measured from study registration to death from any cause (censoring of patients without an event at date of last follow-up)

Interventions

DRUGPASIREOTIDE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS), measured from study registration to radiologically confirmed disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first (censoring of patients without an event at date of last follow-up)	—

Secondary

Measure	Time frame
Overall survival (OS), measured from study registration to death from any cause (censoring of patients without an event at date of last follow-up)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026